Recent Quotes (30 days)

You have no recent quotes
chg | %

Sophiris Bio Inc  

(Public, TSE:SHS)   Watch this stock  
Find more results for TSE:PRX
0.0000
- Close
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 4.25 - 18.20
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -4.35
Shares     -
Beta     -
Inst. own     -
Nov 18, 2014
Sophiris Bio Inc at Stifel Healthcare Conference Add to calendar
Nov 11, 2014
Q3 2014 Sophiris Bio Inc Earnings Release - 10:00AM EST - Add to calendar
Oct 7, 2014
Sophiris Bio Inc at BIO Investor Forum - 11:00AM EDT - Add to calendar
Aug 7, 2014
Q2 2014 Sophiris Bio Inc Earnings Release
  

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -222.98%
Operating margin - -195.80%
EBITD margin - -194.12%
Return on average assets -84.56% -35.16%
Return on average equity -116.07% -63.39%
Employees 8 -
CDP Score - -

Address

1258 Prospect Street
LA JOLLA, CA 92037
United States - Map
+1-858-7771760 (Phone)
+1-858-4125693 (Fax)

Website links

Description

Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.

Officers and directors

Lars G. Ekman M.D., Ph.D. Executive Chairman of the Board
Age: 64
Randall E. Woods President, Chief Executive Officer, Director
Age: 62
Peter T. Slover CPA Chief Financial Officer
Age: 39
Allison J. Hulme Ph.D. Chief Operating Officer, Head - Research & Development
Age: 51
John Geltosky Ph.D. Independent Director
Age: 68
James L. Heppell Independent Director
Age: 58
Gerald T. Proehl Independent Director
Age: 55
Joseph L. Turner Jr. Independent Director
Age: 62